Roth Capital Partners analyst Jonathan Aschoff says NeOnc Technologies Holdings’ (NeOnc Technologies Holdings Stock Quote, Chart, News, Analysts, Financials NYSE:NTHI) lead brain cancer assets could move into pivotal trials by year-end. In a Sept. 24 initiation report, Aschoff launched coverage of NeOnc with a “Buy” rating and US$20.00 target. NeOnc is a clinical-stage oncology company […]
Paradigm Capital analyst Scott McAuley says Spectral Medical’s (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) FDA review remains on track after its Day-100 meeting. McAuley maintained his “Buy” rating and $2.80 target on Spectral. Spectral said it completed its Day-100 meeting with the FDA, reviewing the contents of a Deficiency Letter tied to […]
Share
Tweet
Share
